Fisetin vs FOXO4-DRI
Two senolytics sold on striking mouse data — a flavonoid with one human trial that just reported null, and a peptide with a single landmark mouse study and no human trials at all.
Short answer
Fisetin and FOXO4-DRI are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. What does differ is access, since fisetin is sold over the counter as a supplement, while FOXO4-DRI is sold gray-market as a research chemical.
Fisetin
The most potent senolytic flavonoid in mice, with lifespan data — but the one human trial to report a clinical outcome (ROPE, knee osteoarthritis) was null; other senolytic-hypothesis trials remain unpublished.
Full Fisetin evidence reviewFOXO4-DRI
One landmark mouse study (Baar 2017) showed the interfering peptide selectively killed senescent cells and restored fitness in aged mice — a striking result with zero human trials since, and no legitimate access route.
Full FOXO4-DRI evidence reviewFisetin vs FOXO4-DRI: head to head
- FDA status / approved use
Fisetin
Sold as a dietary supplement, not an approved drug; senolytic use is investigationalFOXO4-DRI
Not an approved drug; no human trials; sold online as a research chemical- Marketed for
Fisetin
Senolytic, anti-agingFOXO4-DRI
Senolytic, healthy aging- Outcome areas
Fisetin
Cellular senescence; Longevity / lifespan; Joint / bone healthFOXO4-DRI
Cellular senescence; Longevity / lifespan- Evidence grade
Fisetin
Preclinical / minimalFOXO4-DRI
Preclinical / minimal- How it works
Fisetin
Senolytic: clears senescent 'zombie' cells, shown mainly in miceFOXO4-DRI
Breaks the FOXO4-p53 bond so senescent cells self-destruct- Route and dosing
Fisetin
Oral supplement, often taken in high intermittent dosesFOXO4-DRI
Injection (gray-market use); no validated human dose- Headline human result
Fisetin
No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCTFOXO4-DRI
Not established- Strongest evidence
Fisetin
Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143FOXO4-DRI
Baar 2017, Cell. Little or no controlled human outcome data for the marketed useFOXO4-DRI evidence reviewPubMed 28340339- Key safety signal
Fisetin
Looks safe as a food compound; long-term safety of high senolytic doses is not establishedFOXO4-DRI
No established safety, purity or dosing basis; no long-term human safety data- How it is obtained
Fisetin
Over the counter as a dietary supplementFOXO4-DRI
Sold gray-market as a research chemical; no approved human product
| Fisetin | FOXO4-DRI | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement, not an approved drug; senolytic use is investigational | Not an approved drug; no human trials; sold online as a research chemical |
| Marketed for | Senolytic, anti-aging | Senolytic, healthy aging |
| Outcome areas | Cellular senescence; Longevity / lifespan; Joint / bone health | Cellular senescence; Longevity / lifespan |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Senolytic: clears senescent 'zombie' cells, shown mainly in mice | Breaks the FOXO4-p53 bond so senescent cells self-destruct |
| Route and dosing | Oral supplement, often taken in high intermittent doses | Injection (gray-market use); no validated human dose |
| Headline human result | No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCT | Not established |
| Strongest evidence | Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143 | Baar 2017, Cell. Little or no controlled human outcome data for the marketed useFOXO4-DRI evidence reviewPubMed 28340339 |
| Key safety signal | Looks safe as a food compound; long-term safety of high senolytic doses is not established | No established safety, purity or dosing basis; no long-term human safety data |
| How it is obtained | Over the counter as a dietary supplement | Sold gray-market as a research chemical; no approved human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
Fisetin is the more human-tested of the two, and that testing has been sobering: the first senolytic-hypothesis trial to report a clinical outcome, ROPE in knee osteoarthritis, found no benefit, though other trials remain unpublished. FOXO4-DRI's evidence is a single, striking 2017 mouse study that has not been followed by any human trial in eight years, and no legitimate product exists to buy. Fisetin at least has decades of food-safety history behind it; FOXO4-DRI does not.
Fisetin fits if
You want the senolytic with an actual, if now null, human trial record and a long food-safety history.
FOXO4-DRI fits if
You're reading about senolytic mechanisms generally rather than looking for something to take — there is no legitimate human access route to this one.
Fisetin vs FOXO4-DRI: common questions
- Is either fisetin or FOXO4-DRI FDA-approved?
- No. Fisetin is sold as a dietary supplement, not an approved drug; senolytic use is investigational. FOXO4-DRI is not an approved drug; no human trials; sold online as a research chemical.
- Which has stronger human evidence, fisetin or FOXO4-DRI?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for fisetin is mouse senolytic, EBioMedicine 2018; for FOXO4-DRI, it is Baar 2017, Cell.
- What are the main safety concerns with fisetin and FOXO4-DRI?
- Fisetin looks safe as a food compound; long-term safety of high senolytic doses is not established. FOXO4-DRI has no established safety, purity or dosing basis; no long-term human safety data.
Key studies behind each
Fisetin
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PubMed 30279143
- Murray KO, Mahoney SA, Ludwig KR, et al. (2025). Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. PubMed 40437670
- Silva M, Wacker DA, Driver BE, et al. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multi-center, randomized, adaptive allocation clinical trial. Trials. PubMed 39434114
- Ji J, Crespi CM, Yee L, et al. (2026). A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design. Ther Adv Med Oncol. PubMed 41835341
FOXO4-DRI
- Baar MP, Brandt RMC, Putavet DA, Klein JDD, et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. PubMed 28340339
- Bourgeois B, Madl T. (2018). Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Letters. PubMed 29683489
- Bourgeois B, Spreitzer E, Platero-Rochart D, Paar M, et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications. PubMed 40593617
- Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nature Reviews Molecular Cell Biology. PubMed 33328614
The full evidence reviews
- Fisetin: a powerful senolytic in mice, unproven in humans
A dietary flavonoid that's the most potent senolytic of its class and extends lifespan in mice — but the human trials that would test the senolytic claim are still ongoing, with no published outcomes.
Updated August 2026
- FOXO4-DRI: an elegant senolytic peptide with zero human evidence
A rationally designed peptide that frees p53 to kill senescent cells and reversed features of aging in mice — but rests on essentially one landmark study, has no human trials, and is sold gray-market with no safety basis.
Updated August 2026